摘要目的 探讨18 F-FDG PET/CT在T细胞淋巴瘤临床再分期、评价疗效、监测复发及提示预后方面的临床价值.方法 回顾性分析34例T细胞淋巴瘤患者的PET/CT显像结果,评价其在临床再分期、评价疗效、监测复发及提示预后方面的价值.结果 34例患者中20例分期Ⅰ～Ⅱ期者治疗后6例分期上调,9例分期下调,5例分期未改变；14例分期Ⅲ～Ⅳ期者治疗后3例分期上调,4例分期下调,7例分期未改变.34例T细胞淋巴瘤患者中12例达完全缓解(CR),11例达部分缓解(PR),2例处于稳定(SD)状态,9例进展(PD).34例患者中有25例至少经6个疗程化疗后行PET/CT检查,疗效较佳组的标准化摄取(SUV)值比疗效不佳组的SUV值小(分别为4.3±3.1和11.2+6.1),差异有统计学意义(P =0.009).8例患者于治疗前后均行PET/CT检查,治疗前后SUV值差异有统计学意义(P=0.000).25例外周T细胞淋巴瘤至少经6个疗程化疗后PET/CT评价疗效较佳组与疗效不佳组的平均生存时间(分别为82.7和39.5个月)差异有统计学意义(P=0.015).结论 T细胞淋巴瘤治疗后行PET/CT检查对于指导临床再分期、评价疗效、监测复发及提示预后有一定意义,有助于临床早期判断疗效及制定个体化治疗方案.

abstractsObjective To investigate the usefulness of 18F-FDG PET/CT imaging in restaging,evaluating the treatment outcome,monitoring relapse and predicting prognosis of T-cell lymphoma.Methods Retrospective analysis of PET/CT image results of thirty-four patients with T-cell lymphoma,and to evaluate its clinical significance in restaging,treatment efficiency,relapse monitor and progrosis prediction.Results Clinical restaging among the 20 stage Ⅰ and Ⅱ patients,6 were ascended,9 descended and 5 unchanged.Restaging among the other 14 stage Ⅲ and Ⅳ patients,3 were ascended,4 descended and 7 unchanged.There were 12 patients in complete remission( CR),11 in partial remission( PR),2 in stable disease(SD)and 9 in progressive disease (PD) among all the 34 patients.There is obvious statistical difference of the standardized uptake value(SUV) between the efficacy group and the inefficacy group after treatment of 6 courses at least in 25 patients among all the 34 patients( P =0.009).There is obvious statistical difference of the SUV value before and after treatment in 8 patients among all the 34 patients(P =0.000).There is obvious statistical difference in the survival time between the efficacy group and the inefficacy group after treatment of 6 courses at least in 25 patients among all the 34 patients( P =0.015 ).Conclusions 18F-FDG PET/CT imaging plays an very important role in guiding clinical restaging,evaluating the treatment outcome,monitoring relapse and predicting prognosis of T-cell lymphoma. It is helpful to establish personalized treatment planning.